• Wondering if Sabra Health Care REIT at around US$20.36 is offering good value or if the easy money has already been made? This article walks through what the current price might be implying about the stock.
• Sabra's share price sits at US$20.36, with returns of 1.3% over 7 days, 2.5% over 30 days, 6.3% year to date and 24.7% over the past year, plus 127.5% over 3 years and 71.5% over 5 years.
• Recent news flow around Sabra has focused on its role as a health care focused REIT and how investors see that sector in the context of income and property exposure. These headlines help frame why the share price and sentiment have shifted over different time frames.
• On Simply Wall St’s 6 point valuation checklist, Sabra Health Care REIT scores 4 out of 6. The rest of this article will walk through the main valuation approaches used to reach that score and then finish with a way to assess value that ties the numbers back to the bigger investment story.

Approach 1: Sabra Health Care REIT Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a company might be worth by projecting its future adjusted funds from operations and then discounting those cash flows back into today’s dollars.

For Sabra Health Care REIT, the model uses last twelve months free cash flow of about $361.6 million as a starting point and then applies analyst estimates for the next few years, with later years extrapolated by Simply Wall St. By 2030, projected free cash flow is $616.4 million, and there is a full set of annual projections through 2035, all expressed in US$ and adjusted for the time value of money.

When those projected cash flows are added together and divided by the number of shares, the model arrives at an estimated intrinsic value of about $52.46 per share. Compared with the recent share price of $20.36, this DCF output suggests Sabra could be 61.2% undervalued on this metric.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Sabra Health Care REIT is undervalued by 61.2%. Track this in your watchlist or portfolio, or discover 50 more high quality undervalued stocks.

Approach 2: Sabra Health Care REIT Price vs Earnings

For profitable companies, the P/E ratio is a useful yardstick because it directly links what you are paying per share to the earnings that each share generates. It lets you see how many dollars investors are currently willing to pay for one dollar of earnings.

What counts as a "normal" or "fair" P/E often reflects a mix of growth expectations and risk. Higher expected earnings growth or lower perceived risk tends to line up with higher P/E ratios, while slower growth or higher risk usually goes with lower P/E ratios.

Sabra Health Care REIT is trading on a P/E of 32.88x. That sits above the Health Care REITs industry average P/E of 24.54x, yet below the peer group average of 83.44x. To make this more specific, Simply Wall St introduces a proprietary “Fair Ratio”, which in this case is 39.40x.

The Fair Ratio is designed to be more tailored than simple peer or industry comparisons because it considers factors such as earnings growth, profit margins, risk profile, industry and market cap together. When Sabra's current P/E of 32.88x is set against the Fair Ratio of 39.40x, the shares screen as trading below that modelled fair level.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 17 top founder-led companies.

Upgrade Your Decision Making: Choose your Sabra Health Care REIT Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives bring Sabra Health Care REIT’s story together with a financial forecast and a fair value by letting you set assumptions for future revenue, earnings, margins and a fair price, then compare that fair value with today’s share price on Simply Wall St’s Community page. Different investors can, for example, build a more optimistic Sabra view that leans on faster senior housing demand and a higher P/E, or a more cautious view that leans on regulatory and execution risks and a lower P/E. As new news or earnings arrive, those Narratives refresh automatically so you can quickly see whether your story for Sabra still matches the numbers.

Do you think there's more to the story for Sabra Health Care REIT? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.